Amalia Mohd Hashim

Dr. Amalia Mohd Hashim

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Food Chemistry
Verified
Journal Article
Closed access
MYMohd Hafis Yuswan
Mohd Hafis Yuswan
NJNurul Hanani A. Jalil
Nurul Hanani A. Jalil
HMHaslina Mohamad
Haslina Mohamad
SKShamsidah Keso
Shamsidah Keso
NMNurhidayatul Asma Mohamad
Nurhidayatul Asma Mohamad
SMShuhaimi Mustafa
Shuhaimi Mustafa

1 June 2021 in Food Chemistry
Verified
Journal Article
Closed access
SSSiti Nurhidayah Sharin
Siti Nurhidayah Sharin
MSMuhamad Shirwan Abdullah Sani
Muhamad Shirwan Abdullah Sani
MJMohd Azwan Jaafar
Mohd Azwan Jaafar
MYMohd Hafis Yuswan
Mohd Hafis Yuswan
NKNur Kartinee Kassim
Nur Kartinee Kassim
AHAmalia Mohd Hashim
Amalia Mohd Hashim

18 May 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
MSMUHAMAD FIRDAUS SYAHMI SAM-ON
MUHAMAD FIRDAUS SYAHMI SAM-ON
SMShuhaimi Mustafa
Shuhaimi Mustafa
AHAmalia Mohd Hashim
Amalia Mohd Hashim
MYMohd Termizi Yusof
Mohd Termizi Yusof
SZShahrizim Zulkifly
Shahrizim Zulkifly
MAMohd Shaufi Bin Mohd Asrore
Mohd Shaufi Bin Mohd Asrore

24 January 2022 in Microbial Pathogenesis
Verified
Journal Article
Closed access
MSMUHAMAD FIRDAUS SYAHMI SAM-ON
MUHAMAD FIRDAUS SYAHMI SAM-ON
SMShuhaimi Mustafa
Shuhaimi Mustafa
MYMohd Termizi Yusof
Mohd Termizi Yusof
AHAmalia Mohd Hashim
Amalia Mohd Hashim
SASahar Abbasiliasi
Sahar Abbasiliasi
MRMuhamad Akhmal Hakim Roslan
Muhamad Akhmal Hakim Roslan

16 December 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MTMariam Dayana Mohd Taha
Mariam Dayana Mohd Taha
MJMohammad Fahrulazri Mohd Jaini
Mohammad Fahrulazri Mohd Jaini
NSNoor Baity Saidi
Noor Baity Saidi
RRRaha Abdul Rahim
Raha Abdul Rahim
USUmi Kalsom Md Shah
Umi Kalsom Md Shah
AHAmalia Mohd Hashim
Amalia Mohd Hashim
Dieback disease caused by Erwinia mallotivora is a major threat to papaya plantation in Malaysia. The current study was conducted to evaluate the potential of endophytic lactic acid bacteria (LAB) isolated from papaya seeds for disease suppression of papaya dieback. Two hundred and thirty isolates were screened against E. mallotivora BT-MARDI, and the inhibitory activity of the isolates against the pathogen was ranging from 11.7–23.7 mm inhibition zones. The synergistic experiments revealed that combination of W. cibaria PPKSD19 and Lactococcus lactis subsp. lactis PPSSD39 increased antibacterial activity against the pathogen. The antibacterial activity was partially due to the production of bacteriocin-like inhibitory substances (BLIS). The nursery experiment confirmed that the application of bacterial consortium W. cibaria PPKSD19 and L. lactis subsp. lactis PPSSD39 significantly reduced disease severity to 19% and increased biocontrol efficacy to 69% of infected papaya plants after 18 days of treatment. This study showed that W. cibaria PPKSD19 and L. lactis subsp. lactis PPSSD39 are potential candidate as biocontrol agents against papaya dieback disease.

14 December 2021 in PeerJ
Verified
Journal Article
Open access
PDF file
NBNurul Hana Zainal Baharin
Nurul Hana Zainal Baharin
NMNur Fadhilah Khairil Mokhtar
Nur Fadhilah Khairil Mokhtar
MDMohd Nasir Mohd Desa
Mohd Nasir Mohd Desa
BGBanulata Gopalsamy
Banulata Gopalsamy
NZNor Nadiha Mohd Zaki
Nor Nadiha Mohd Zaki
SMShuhaimi Mustafa
Shuhaimi Mustafa
The emergence of antibiotic-resistant bacteria has become a significant and ever-increasing threat to global public health, increasing both morbidity and mortality rates, and the financial burden on health services. Infection by drug-resistant bacteria is anticipated to contribute to the demise of almost 10 million people by the year 2050 unless a competent and effective response is devised to engage with this issue. The emergence and spread of resistance are commonly caused by the excessive or inappropriate use of antibiotics and substandard pharmaceuticals. It arises when pathogens adapt to different conditions and develop self-defence mechanisms. Currently, novel antimicrobial peptides (AMPs) have been reported to be the sole cure for some clinical cases of infectious diseases such as sepsis and skin infections, although these agents may, on occasion, require administration together with an adjunctive low-dose antibiotic. Although AMPs are a promising alternative form of anti-microbial therapy and easily applied in the medical sector, they still have limitations that should not be taken lightly. Hence, this review explores the characteristics, advantages and disadvantages of AMPs for their potential in treating antibiotic-resistant pathogens.